Property | Value |
?:abstract
|
-
In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
|
?:creator
|
|
?:doi
|
-
10.1007/s00296-020-04584-7
|
?:doi
|
|
?:journal
|
|
?:license
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/7bb042dbf90180d4c095dd2fd431e6a0419cac3e.json
|
?:pmc_json_files
|
-
document_parses/pmc_json/PMC7167494.xml.json
|
?:pmcid
|
|
?:pmid
|
|
?:pmid
|
|
?:publication_isRelatedTo_Disease
|
|
?:sha_id
|
|
?:source
|
|
?:title
|
-
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
|
?:type
|
|
?:year
|
|